Table 1.
Early RA cohort demographics
| RA-MAP TACERA cohort | NEAC | |||
| NEAC lymphocyte methylome and transcriptome cohorts | ||||
| CD4+ T cell | CD19+ B cell | |||
| Number (n) | 191 | 41 | 41 | |
| Age, years | 55 (20–84) | 58 (27–74) | 58 (27–74) | |
| Female, n (%) | 116 (61%) | 26 (63%) | 30 (73%) | |
| RF positive, n (%) | 155* (90%) | 23 (56%) | 26 (63%) | |
| ACPA positive, n (%) | 147* (85%) | 17 (41%) | 22 (54%) | |
| DAS-28-CRP | 5.27 (2.23–8.14) | 4.61 (1.26–6.53) | 4.36 (1.26–6.53) | |
| CRP (mg/L) | 8.65 (1-136) | 9 (5–13) | 9.5 (4–53) | |
| Erythrocyte sedimentation rate (mm/h) | 28 (2–113) | 19 (7–32) | 20.5 (2–86) | |
| DMARDS initiated | Number with available data | 175 | ||
| MTX | 144 (82%) | |||
| SSZ | 10 (6%) | |||
| HCQ | 91 (52%) | |||
| LFU | 0 | |||
| None | 0 | |||
| Glucocorticoid | 124 (71%) | |||
*Missing data for 18 patients.
ACPA, anti-citrullinated protein/peptide antibody; CRP, C reactive protein; DAS-28, disease activity score; DMARDS, disease-modifying anti-rheumatic drugs; HCQ, hydroxychloroquine; LFU, leflunomide; MTX, methotrexate; NEAC, Newcastle Early Arthritis Clinic; RA, rheumatoid arthritis; RF, rheumatoid factor; SSZ, sulfasalazine; TACERA, Towards A CurE for RA.